RxDoctor Payments Data

Scott Chae, MD

Gastroenterology · Edison, NJNPI 1851409650

Payments from drug & device makers

$16,106in general payments, 2019–2025

Across 729 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$4K
  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Fujifilm Healthcare Americas Corporation$909
  • Johnson & Johnson$671
  • Redhill Biopharma Inc.$662
  • plus $5K from 21 others

What the payments were for

  • Consulting fees$2,10013%
  • Food & beverage$12,94480%
  • Education$1531%
  • Other$9096%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,106 in reported general payments places this provider in the 85th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$422,664
Medicare patients
805
Services billed
2,889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib11$77,337
LinzessLinaclotide88$73,870
VemlidyTenofovir Alafenamide38$59,022
TrulancePlecanatide11$12,053
ViberziEluxadoline12$10,413
Mesalamine23$9,685
AprisoMesalamine12$8,907
OxycontinOxycodone Hcl12$7,046
Pantoprazole Sodium455$6,664
NexiumEsomeprazole Magnesium16$6,622
Dexlansoprazole DrDexlansoprazole16$5,136
Tenofovir Disoproxil Fumarate17$3,825
Ursodiol17$2,868
Omeprazole147$1,687
Sucralfate57$1,502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Linzess, Viberzi$3,740$161,620111 claims
GileadVemlidy$3,943$59,02238 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Apriso$1,270$20,96023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Edison

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →